115 results
SC TO-T
EX-99
Corerx Inc
11 Mar 24
Third party tender offer statement
4:05pm
”) with capabilities spanning pre-investigational new drug development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms … -to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global
8-K
EX-99.2
SCTL
Societal CDMO Inc
28 Feb 24
Form of Tender and Support Agreement
4:58pm
an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging
CoreRx … manufacturing, and a range of packaging services. The prospects for this combined entity to establish itself as a preferred CDMO partner in the small molecule
8-K
EX-99.2
v63hgxaph
8 Nov 23
Societal CDMO Reports Third Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
two2ejihu cf
8 Nov 23
Societal CDMO Reports Third Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
g9ejeidkwss3l lby
20 Sep 23
Societal CDMO announces corporate restructuring
4:10pm
424B5
qr2km
25 Aug 23
Prospectus supplement for primary offering
8:06pm
424B5
uiijf8n dt1hpei3k7
23 Aug 23
Prospectus supplement for primary offering
4:38pm
8-K
EX-99.2
y0n4j0b
14 Aug 23
Societal CDMO Reports Second Quarter 2023 Financial Results
4:28pm
8-K
EX-99.1
g3caxtv e1l2i6nm
14 Aug 23
Societal CDMO Reports Second Quarter 2023 Financial Results
4:28pm
8-K
EX-99.1
kefw8ott2
10 May 23
Societal CDMO Reports First Quarter 2023 Financial Results
4:22pm
8-K
EX-99.2
kf598oiha6p06l
10 May 23
Societal CDMO Reports First Quarter 2023 Financial Results
4:22pm
424B5
wdlvks 3bvjq2je
13 Dec 22
Prospectus supplement for primary offering
5:29pm
424B5
5v7qd9x
13 Dec 22
Prospectus supplement for primary offering
5:26pm
424B5
ks3s1z80egpk8o
12 Dec 22
Prospectus supplement for primary offering
7:16am